Kazia Therapeutics (NASDAQ: KZIA) holder reports 18.5% stake in ADS
Rhea-AI Filing Summary
Kazia Therapeutics Ltd reports beneficial ownership of 2,114,649 American Depositary Shares, representing 18.5% of the class as of May 26, 2026. The filing calculates the class base on 11,426,899 ADS outstanding as of March 12, 2026, per the issuer's Form F-3. The schedule lists the reporting person as Jorey Chernett with sole voting and dispositive power over the disclosed ADS.
Positive
- None.
Negative
- None.
Insights
Significant single-holder stake disclosed: 18.5% ownership.
The filing shows Jorey Chernett beneficially owns 2,114,649 ADS, equal to 18.5% of the class using an March 12, 2026 outstanding base of 11,426,899 ADS. This is a large, disclosed beneficial position in a single holder.
Concentration of voting power can affect governance outcomes and potential coordination with other holders. Subsequent disclosures or amendments would clarify whether holdings change or if any voting agreements exist; timing not specified in the provided excerpt.
Filing type and calculation method are explicit; disclosure aligns with Schedule 13G/A norms.
The schedule cites the issuer's Form F-3 for the 11,426,899 ADS outstanding figure and provides the Reporting Person's address, citizenship, and voting/dispositive powers. The filing is signed and dated 05/27/2026.
Compliance implications are routine: the amendment updates beneficial ownership data. Any material change in ownership or voting arrangements would typically trigger further amendments per applicable rules.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficially owned regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.